

|   |  |                                     |                          |
|---|--|-------------------------------------|--------------------------|
| FORM PTO-1449<br><i>CIPE JC39</i><br>SEP 01 2004<br>PATENT AND TRADEMARK OFFICE | U.S. DEPARTMENT OF COMMERCE<br>PATENT AND TRADEMARK OFFICE<br><br>INFORMATION DISCLOSURE<br>STATEMENT BY APPLICANT | ATTY. DOCKET NO.<br>ABX-PF2         | APPLN. NO.<br>10/038,591 |
|   |  | APPLICANT<br>Bruce D. C. hen et al. | CONFIRMATION<br>NO. 1445 |
|   |  | FILING DATE<br>January 4, 2002      | GROUP<br>1642            |

## UNITED STATES. PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE       | NAME          | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|------------------|-----------------|------------|---------------|-------|----------|----------------------------|
| Lap              | 6,146,629       | 11/14/2000 | Dagan, et al. | 424   | 149.1    |                            |

## FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE       | COUNTRY | CLASS | SUBCLASS | TRANSLATION |    |
|------------------|-----------------|------------|---------|-------|----------|-------------|----|
|                  |                 |            |         |       |          | YES         | NO |
| WD               | WO 96/33735     | 10/31/1996 | PCT     | A61K  | 39/00    |             | X  |
| WD               | WO 00/56772     | 09/28/2000 | PCT     | C07K  | 16/24    |             | X  |

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

|                  |  |
|------------------|--|
| EXAMINER INITIAL |  |
| WD               | Li, S.-L. et al., "Single-chain Antibodies Against Human Insulin-like Growth Factor I Receptor: Expression, Purification and Effect on Tumor Growth," <i>Cancer Immunology and Immunotherapy</i> , 49:243-252 (2000).  |
| WD               | Hermanto, U. et al., "Inhibition of Mitogen-activated Protein Kinase Kinase Selectively Inhibits Cell Proliferation in Human Breast Cancer Cells Displaying Enhanced Insulin-like Growth Factor I-mediated Mitogen-activated Protein Kinase Activation," <i>Cell Growth &amp; Differentiation</i> , 11:655-664 (2000). |
|                  |  |
|                  |  |
|                  |  |
|                  |  |
|                  |  |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

|  |  |                                   |                          |
|--|--|-----------------------------------|--------------------------|
| FORM PTO-1449                                    | U.S. DEPARTMENT OF COMMERCE<br>PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO.<br>ABX-PF2       | APPLN. NO.<br>10/038,591 |
| INFORMATION DISCLOSURE<br>STATEMENT BY APPLICANT |  | APPLICANT<br>Bruce D. C hen t al. | CONFIRMATION<br>NO. 1445 |
|  |  | FILING DATE<br>January 4, 2002    | GROUP<br>1642            |

*O I P E JCSB  
01/01/2002*

## UNITED STATES. PATENT DOCUMENTS


| EXAMINER INITIAL | DOCUMENT NUMBER | DATE     | NAME               | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|------------------|-----------------|----------|--------------------|-------|----------|----------------------------|
| JAH              | 4,399,216       | 08/16/83 | Axel et al.        | 435   | 6        |                            |
| 1                | 4,510,245       | 04/09/85 | Cousens et al.     | 435   | 172.3    |                            |
|                  | 4,634,665       | 01/06/87 | Axel et al.        | 435   | 68       |                            |
|                  | 4,740,461       | 04/26/88 | Kaufman            | 435   | 68       |                            |
|                  | 4,912,040       | 03/27/90 | Kaufman et al.     | 435   | 69.6     |                            |
|                  | 4,959,455       | 09/25/90 | Clark et al.       | 530   | 351      |                            |
|                  | 4,968,516       | 11/06/90 | Koszinowki et al.  | 435   | 172.3    |                            |
|                  | 5,151,510       | 09/29/92 | Stec et al.        | 536   | 27       |                            |
|                  | 5,168,062       | 12/01/92 | Stinski            | 435   | 240.2    |                            |
|                  | 5,179,017       | 01/12/93 | Axel et al.        | 435   | 240.2    |                            |
|                  | 5,223,409       | 06/29/93 | Ladner et al.      | 435   | 69.7     |                            |
|                  | 5,530,101       | 06/25/96 | Queen et al.       | 530   | 387.3    |                            |
|                  | 5,545,806       | 08/13/96 | Lonberg et al.     | 800   | 2        |                            |
|                  | 5,545,807       | 08/13/96 | Surani et al.      | 800   | 2        |                            |
|                  | 5,585,089       | 12/17/96 | Queen et al.       | 424   | 133.1    |                            |
|                  | 5,587,458       | 12/24/96 | King et al.        | 530   | 387.3    |                            |
|                  | 5,591,669       | 01/07/97 | Krimpenfort et al. | 800   | 2        |                            |
|                  | 5,612,205       | 03/18/97 | Kay et al.         | 435   | 172.3    |                            |
|                  | 5,625,126       | 04/29/97 | Lonberg et al.     | 800   | 2        |                            |
|                  | 5,625,825       | 04/29/97 | Rostoker et al.    | 395   | 730      |                            |
|                  | 5,633,425       | 05/27/97 | Lonberg et al.     | 800   | 2        |                            |
|                  | 5,643,763       | 07/01/97 | Dunn et al.        | 435   | 911      |                            |
|                  | 5,661,016       | 08/26/97 | Lonberg et al.     | 435   | 172.3    |                            |
|                  | 5,693,761       | 12/02/97 | Queen et al.       | 536   | 23.53    |                            |
|                  | 5,693,792       | 12/02/97 | Torii et al.       | 540   | 358      |                            |
| V                | 5,714,350       | 02/03/98 | Co et al.          | 435   | 69.6     |                            |
| LH               | 5,721,367       | 02/24/98 | Kay et al.         | 800   | 2        |                            |

EXAMINER

DATE CONSIDERED

11/22/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE  
STATEMENT BY APPLICANTATTY. DOCKET NO.  
ABX-PF2APPLN. NO.  
10/038,591APPLICANT  
Bruc D. C hen et al.CONFIRMATION  
NO. 1445FILING DATE  
January 4, 2002GROUP  
1642

## UNITED STATES. PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE     | NAME                | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|------------------|-----------------|----------|---------------------|-------|----------|----------------------------|
| JPA              | 5,741,957       | 04/21/98 | Deboer et al.       | 800   | 2        |                            |
| J                | 5,747,498       | 05/05/98 | Schnur et al.       | 514   | 259      |                            |
|                  | 5,750,172       | 05/12/98 | Meade et al.        | 426   | 580      |                            |
|                  | 5,756,687       | 05/26/98 | Denman et al.       | 530   | 412      |                            |
|                  | 5,770,429       | 06/23/98 | Lonberg et al.      | 435   | 240.2    |                            |
|                  | 5,777,085       | 07/07/98 | Co et al.           | 530   | 388.23   |                            |
|                  | 5,789,215       | 08/04/98 | Berns et al.        | 435   | 172.3    |                            |
|                  | 5,789,650       | 08/04/98 | Lonberg et al.      | 800   | 2        |                            |
|                  | 5,792,783       | 08/11/98 | Tang et al.         | 514   | 397      |                            |
|                  | 5,814,318       | 09/29/98 | Lonberg et al.      | 424   | 184.1    |                            |
|                  | 5,827,690       | 10/27/98 | Meade et al.        | 435   | 69.6     |                            |
|                  | 5,834,504       | 11/10/98 | Tang et al.         | 514   | 418      |                            |
|                  | 5,861,510       | 01/19/99 | Piscopio et al.     | 544   | 131      |                            |
|                  | 5,863,949       | 01/26/99 | Robinson et al.     | 514   | 575      |                            |
|                  | 5,877,305       | 03/02/99 | Huston et al.       | 536   | 23.53    |                            |
|                  | 5,883,113       | 03/16/99 | Tang et al.         | 514   | 418      |                            |
|                  | 5,886,020       | 03/23/99 | Tang et al.         | 514   | 418      |                            |
|                  | 5,886,152       | 03/23/99 | Nakatani et al.     | 530   | 387.3    |                            |
|                  | 5,916,771       | 06/29/99 | Hori et al.         | 435   | 69.6     |                            |
|                  | 5,939,598       | 08/17/99 | Kucherlapati et al. | 800   | 25       |                            |
|                  | 5,985,615       | 11/16/99 | Jakobovits et al.   | 435   | 69.6     |                            |
|                  | 5,994,619       | 11/30/99 | Stice et al.        | 800   | 2        |                            |
|                  | 5,998,209       | 12/07/99 | Jokobovits et al.   | 435   | 463      |                            |
|                  | 6,054,297       | 04/25/00 | Carter et al.       | 435   | 69.6     |                            |
|                  | 6,075,181       | 06/13/00 | Kucherlapati et al. | 800   | 25       |                            |
| X                | 6,091,001       | 07/18/00 | Jakobovits et al.   | 800   | 18       |                            |
| LH               | 6,114,598       | 09/05/00 | Kucherlapati et al. | 800   | 18       |                            |

EXAMINER

DATE CONSIDERED

1/29/01

EXAMINER: Initial if citation considered, whether or not citation is in compliance with MPEP 609; Draw line through citation if not compliance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE  
STATEMENT BY APPLICANTATTY. DOCKET NO.  
ABX-PF2APPLN. NO.  
10/038,591APPLICANT  
Bruce D. Cohen et al.CONFIRMATION  
NO. 1445FILING DATE  
January 4, 2002GROUP  
1642

## UNITED STATES. PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE     | NAME              | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|------------------|-----------------|----------|-------------------|-------|----------|----------------------------|
| LH               | 6,130,364       | 10/10/00 | Jakobovits et al. | 4800  | 6        |                            |

## FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE     | COUNTRY | CLASS | SUBCLASS | TRANSLATION |    |
|------------------|-----------------|----------|---------|-------|----------|-------------|----|
|                  |                 |          |         |       |          | YES         | NO |
| LH               | 0 216 846       | 04/08/87 | EPO     | C12N  | 15/00    |             |    |
|                  | 0 256 055       | 02/24/88 | EPO     | C12N  | 15/52    |             |    |
|                  | 0 323 997       | 07/19/89 | EPO     | C12N  | 15/12    |             |    |
|                  | 0 338 841       | 10/25/89 | EPO     | C12N  | 15/00    |             |    |
|                  | 0 606 046       | 07/13/94 | EPO     | C07D  | 213/42   |             |    |
|                  | 0 780 386       | 06/25/97 | EPO     | C07D  | 309/08   |             |    |
|                  | 0 818 442       | 01/14/98 | EPO     | C07C  | 317/44   |             |    |
|                  | 0 931 788       | 07/28/99 | EPO     | C07C  | 311/03   |             |    |
|                  | 1 004 578       | 05/31/00 | EPO     | C07D  | 207/28   |             |    |
|                  | WO 90/05719     | 05/31/90 | PCT     | C07C  | 323/62   |             |    |
|                  | WO 91/10741     | 07/25/91 | PCT     | C12P  | 21/06    |             |    |
|                  | WO 91/17271     | 11/14/91 | PCT     | C12Q  | 1/70     |             |    |
|                  | WO 92/01047     | 01/23/92 | PCT     | C12N  | 15/00    |             |    |
|                  | WO 92/02190     | 02/20/92 | PCT     | A61C  | 7/00     |             |    |
|                  | WO 92/09690     | 06/11/92 | PCT     | C12N  | 15/00    |             |    |
|                  | WO 92/15679     | 09/17/92 | PCT     | C12N  | 15/10    |             |    |
| LH               | WO 92/18619     | 10/29/92 | PCT     | C12N  | 7/01     |             |    |
| LH               | WO 92/20791     | 11/26/92 | PCT     | C12N  | 15/00    |             |    |

EXAMINER

DATE CONSIDERED

11/22/04

EXAMINER: Initial if citation considered, whether or not citation is in compliance with MPEP 609; Draw line through citation if no information and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE  
STATEMENT BY APPLICANTATTY. DOCKET NO.  
ABX-PF2APPLN. NO.  
10/038,591APPLICANT  
Bruce D. Cohen et al.CONFIRMATION  
NO. 1445FILING DATE  
January 4, 2002GROUP  
1642

## FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE     | COUNTRY | CLASS | SUBCLASS | TRANSLATION |    |
|------------------|-----------------|----------|---------|-------|----------|-------------|----|
|                  |                 |          |         |       |          | YES         | NO |
|                  | WO 93/01288     | 01/21/93 | PCT     | C12N  | 15/13    |             |    |
|                  | WO 93/06213     | 04/01/93 | PCT     | C12N  | 15/00    |             |    |
|                  | WO 94/02602     | 02/03/94 | PCT     | C12N  | 15/00    |             |    |
|                  | WO 95/19970     | 07/27/95 | PCT     | C07D  | 239/70   |             |    |
|                  | WO 95/21613     | 08/17/95 | PCT     | A16K  | 31/24    |             |    |
|                  | WO 96/27583     | 09/12/96 | PCT     | C07C  | 31/29    |             |    |
|                  | WO 96/33172     | 10/24/96 | PCT     | C07D  | 211/96   |             |    |
|                  | WO 96/33735     | 10/31/96 | PCT     | A61K  | 39/00    |             |    |
|                  | WO 96/34096     | 10/31/96 | PCT     | C12N  | 15/00    |             |    |
|                  | WO 97/13760     | 04/17/97 | PCT     | C07D  | 239/70   |             |    |
|                  | WO 97/22596     | 06/26/97 | PCT     | C07D  | 239/94   |             |    |
|                  | WO 97/32856     | 09/12/97 | PCT     | C07D  | 239/94   |             |    |
|                  | WO 98/02434     | 01/22/98 | PCT     | C07D  | 405/04   |             |    |
|                  | WO 98/02437     | 01/22/98 | PCT     | C07D  | 471/04   |             |    |
|                  | WO 98/02438     | 01/22/98 | PCT     | C07D  | 471/04   |             |    |
|                  | WO 98/03516     | 01/29/98 | PCT     | C07F  | 9/30     |             |    |
|                  | WO 98/07697     | 02/26/98 | PCT     | C07D  | 211/58   |             |    |
|                  | WO 98/14451     | 04/09/98 | PCT     | C07D  | 487/04   |             |    |
|                  | WO 98/16654     | 04/23/98 | PCT     | C12P  | 21/00    |             |    |
|                  | WO 98/24893     | 06/11/98 | PCT     | C12N  | 15/00    |             |    |
|                  | WO 98/30566     | 07/16/98 | PCT     | C07D  | 493/08   |             |    |

EXAMINER

DATE CONSIDERED 11/22/04

EXAMINER: Initial if citation considered, whether or not citation is in compliance with MPEP 609; Draw line through citation if not in compliance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE  
STATEMENT BY APPLICANTATTY. DOCKET NO.  
ABX-PF2APPLN. NO.  
10/038,591APPLICANT  
Bruc D. Cohen et al.CONFIRMATION  
NO. 1445FILING DATE  
January 4, 2002GROUP  
1642

## FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE     | COUNTRY | CLASS | SUBCLASS | TRANSLATION |    |
|------------------|-----------------|----------|---------|-------|----------|-------------|----|
|                  |                 |          |         |       |          | YES         | NO |
| DL               | WO 98/33768     | 08/06/98 | PCT     | C07C  | 311/29   |             |    |
|                  | WO 98/34915     | 08/13/98 | PCT     | C07C  | 317/44   |             |    |
|                  | WO 98/34918     | 08/13/98 | PCT     | C07D  | 211/62   |             |    |
|                  | WO 98/50356     | 11/12/98 | PCT     | C07D  | 207/09   |             |    |
|                  | WO 98/50433     | 11/12/98 | PCT     | C07K  | 16/00    |             |    |
|                  | WO 98/54093     | 12/03/98 | PCT     | C01D  | 293/72   |             |    |
|                  | WO 99/07675     | 02/18/99 | PCT     | C07C  | 311/29   |             |    |
|                  | WO 99/10349     | 03/04/99 | PCT     | C07D  | 487/04   |             |    |
|                  | WO 99/16755     | 04/08/99 | PCT     | C07D  | 235/08   |             |    |
|                  | WO 99/24440     | 05/20/99 | PCT     | C07D  | 495/04   |             |    |
|                  | WO 99/29667     | 06/17/99 | PCT     | C07D  | 211/16   |             |    |
|                  | WO 99/35132     | 07/15/99 | PCT     | C07D  | 239/94   |             |    |
|                  | WO 99/35146     | 07/15/99 | PCT     | C07D  | 471/04   |             |    |
|                  | WO 99/45031     | 09/10/99 | PCT     | C07K  | 16/28    |             |    |
|                  | WO 99/52889     | 10/21/99 | PCT     | C07D  | 309/14   |             |    |
|                  | WO 99/52910     | 10/21/99 | PCT     | C07D  | 493/08   |             |    |
|                  | WO 99/53049     | 10/21/99 | PCT     | C12N  | 15/10    |             |    |
|                  | WO 99/61422     | 12/02/99 | PCT     | C07D  | 209/04   |             |    |
|                  | WO 99/62890     | 12/09/99 | PCT     | C07D  | 275/03   |             |    |
| WJ               | WO 00/09560     | 02/24/00 | PCT     | C07K  | 16/00    |             |    |
| LG               | WO 00/37504     | 06/29/00 | PCT     | C07K  | 16/28    |             |    |

EXAMINER

DATE CONSIDERED

11/22/01

EXAMINER: Initial if citation considered, whether or not citation is in compliance with MPEP 609; Draw line through citation if not in compliance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE  
STATEMENT BY APPLICANTATTY. DOCKET NO.  
ABX-PF2APPLN. NO.  
10/038,591APPLICANT  
Bruce D. Cohen et al.CONFIRMATION  
NO. 1445FILING DATE  
January 4, 2002GROUP  
1642

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


| EXAMINER INITIAL |  |
|------------------|--|
| LJH              | Altschul et al., "Basic local alignment search tool," <i>Journal of Molecular Biology</i> , 215(1):403-410 (1990)  |
| ( )              | Altschul et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs," <i>Nucleic Acids Research</i> , 25(17):3389-402 (1997)  |
|                  | Arteaga et al., "Interference of the IGF system as a strategy to inhibit breast cancer growth," <i>Breast Cancer Research Treatment</i> , 22:101-106 (1992)  |
|                  | Arteaga et al., "Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice," <i>Journal of Clinical Investigation</i> , 84:1418-1423 (1989)                               |
|                  | Barbas et al., "Assembly of combinatorial antibody libraries on phage surfaces: the gene III site," <i>PNAS</i> , 88:7978-7982 (1991)  |
|                  | Barkan, "New options for diagnosing and treating acromegaly," <i>Cleveland Clinic Journal of Medicine</i> , 65(7):343-349 (1998)   |
|                  | Bayes-Genis et al., "The insulin-like growth factor axis. A review of atherosclerosis and restenosis," <i>Circulation Research</i> , 86(2):125-130 (2000)  |
|                  | Bird et al., "Single-chain antigen-binding proteins," <i>Science</i> , 242:423-426 (1988)  |
|                  | Bowie et al., "A method to identify protein sequences that fold into a known three-dimensional structure," <i>Science</i> , 253:164-170 (1991)   |
|                  | Butler et al., "Stimulation of tumor growth by recombinant human insulin-like growth factor-I (IGF-I) is dependent on the dose and the level of IGF-I receptor expression," <i>Cancer Research</i> , 58:3021-3027 (1998) |
| ✓                | Chothia et al., "Canonical structures for the hypervariable regions of immunoglobulins," <i>Journal of Molecular Biology</i> , 196:901-917 (1987)  |
| ✓                | Chothia et al., "Conformations of immunoglobulin hypervariable regions," <i>Nature</i> , 342:877-883 (1989)  |
| RM               | Clackson et al., "Making antibody fragments using phage display libraries," <i>Nature</i> , 352:624-628 (1991)   |

EXAMINER

DATE CONSIDERED

11/22/01

EXAMINER: Initial if citation considered, whether or not citation is in compliance with MPEP 609; Draw line through citation if not confirmed and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE  
STATEMENT BY APPLICANTATTY. DOCKET NO.  
ABX-PF2APPLN. NO.  
10/038,591APPLICANT  
Bruce D. Cohen et al.CONFIRMATION  
NO. 1445FILING DATE  
January 4, 2002GROUP  
1642

|                    |  |
|--------------------|--|
| <i>[Signature]</i> | Cullen et al., "Insulin-like growth factor receptor expression and function in human breast cancer," <i>Cancer Research</i> , 50: 48-53 (1990)   |
| <i>[Signature]</i> | Cullen et al., "Glutathione S-transferase $\pi$ amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors," <i>Cancer Research</i> , 63: 8097-8102 (2003) |
|                    | D'Ambrosio et al., "A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells <i>in vivo</i> and inhibits tumorigenesis, <i>Cancer Research</i> , 56:4013-4020 (1996)                            |
|                    | DiGiovanni et al., "Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice," <i>PNAS</i> , 97(7):3455-3460 (2000)   |
|                    | Drexhage et al., "Endocrine autoimmune diseases," <i>Netherlands Journal of Medicine</i> , 45:285-293 (1994)   |
|                    | Du Pasquier, "Evolution of the immune system," <i>Fundamental Immunology, Second Edition</i> , edited by William E. Paul, Raven Press Ltd., NY, 139-165 (1989)   |
|                    | Evans et al., "Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists," <i>Journal of Medicinal Chemistry</i> , 30:1229-1239 (1987)   |
|                    | Fagerstam et al., "Detection of antigen-antibody interactions by surface plasmon resonance. Applications to epitope mapping," <i>Journal of Molecular Recognition</i> , 3:(5,6):208-214 (1990)                               |
|                    | Fanger et al., "Production and use of anti-FcR bispecific antibodies," <i>Immunomethods</i> , 4:72-81 (1994)   |
|                    | Fauchere, "Elements for the rational drug design of peptides drugs," <i>Advances in Drug Research</i> , 15:29-69 (1986)  |
|                    | Foekens et al., "Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer," <i>Cancer Research</i> , 49:7002-7009 (1989)                             |
| <i>[Signature]</i> | Freed et al., "Insulin-like growth factor-I and its autocrine role in growth of MCF-7 human breast cancer cells in culture," <i>Journal of Molecular Endocrinology</i> , 3:183-189 (1989)                                    |
| <i>[Signature]</i> | Fuchs et al., "Targeting recombinant antibodies to the surface of <i>Escherichia coli</i> : fusion to a peptidoglycan associated lipoprotein," <i>Biotechnology</i> , 9:1369-1372 (1991)                                     |
| <i>[Signature]</i> | Galfre et al., "Preparation of monoclonal antibodies: strategies and procedures," <i>Methods in Enzymology</i> , 73:3-46 (1981)  |

EXAMINER

DATE CONSIDERED

*[Signature]*

EXAMINER: Initial if citation considered, whether or not citation is in compliance with MPEP 609; Draw line through citation if not in compliance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE  
STATEMENT BY APPLICANTATTY. DOCKET NO.  
ABX-PF2APPLN. NO.  
10/038,591APPLICANT  
Bruce D. Cohen et al.CONFIRMATION  
NO. 1445FILING DATE  
January 4, 2002GROUP  
1642

|  |  |
|--|--|
|  | Garrad et al., "F <sub>AB</sub> assembly and enrichment in a monovalent phage display system," <i>Biotechnology</i> , 9:1373-1377 (1991)   |
|  | Geran, et al., "Protocols for screening chemical agents and natural products against animal tumors and other biological systems," <i>Cancer Chemotherapy Reports</i> , 3(2):1-104 (1972)                                   |
|  | Goldring et al., "Cytokines and cell growth control," <i>Critical Reviews in Eukaryotic Gene Expression</i> , 1:31-326 (1991)  |
|  | Gonnet et al., "Exhaustive matching of the entire protein sequence database," <i>Science</i> , 256:1443-1445 (1992)  |
|  | Gram et al., "In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library," <i>PNAS</i> , 89:3576-3580 (1992)   |
|  | Green et al., "Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs," <i>Nature Genetics</i> , 7:13-21 (1994)  |
|  | Green et al., "Regulation of B cell development by variable gene complexity in mice reconstituted with human immunoglobulin yeast artificial chromosomes," <i>Journal of Experimental Medicine</i> , 188(3):483-495 (1998) |
|  | Griffiths et al., "Human anti-self antibodies with high specificity from phage display libraries," <i>The EMBO Journal</i> , 12(2):725-734 (1993)  |
|  | Grimberg et al., "Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis," <i>Journal of Cellular Physiology</i> , 183:1-9 (2000)   |
|  | Guo et al., "Characterization of insulinlike growth factor I receptors in human colon cancer," <i>Gastroenterology</i> , 102(4):1101-1108 (1992)   |
|  | Harrington et al., "c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines," <i>The EMBO Journal</i> , 13(14):3286-3295 (1994)  |
|  | Hawkins et al., "Selection of phage antibodies by binding affinity mimicking affinity maturation," <i>Journal of Molecular Biology</i> , 226:889-896 (1992)  |
|  | Hay et al., "Bacteriophage cloning and <i>Escherichia coli</i> expression of a human IgM Fab," <i>Hum. Antibod. Hybridomas</i> , 3:81-85 (1992)  |
|  | Hockenberry et al., "Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death," <i>Nature</i> , 348:334-336 (1990)   |

EXAMINER

DATE CONSIDERED

1/22/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not considered. Include copy of this form with next communication to applicant.



U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE  
  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

|                                   |                          |
|-----------------------------------|--------------------------|
| ATTY. DOCKET NO.<br>ABX-PF2       | APPLN. NO.<br>10/038,591 |
| APPLICANT<br>Bruc D. C hen et al. | CONFIRMATION<br>NO. 1445 |
| FILING DATE<br>January 4, 2002    | GROUP<br>1642            |

|  |
|--|
| Holliger et al., "Diabodies: small bivalent and bispecific antibody fragments," <i>PNAS</i> , 90:6444-6448 (1993)  |
| Hoogenboom et al., "Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains," <i>Nucleic Acids Research</i> , 19(15):4133-4137 (1991)                   |
| Huse et al., "Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda," <i>Science</i> , 246:1275-1281 (1989)   |
| Huston et al., "Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in <i>Escherichia coli</i> ," <i>PNAS</i> , 85:5879-5883 (1988)              |
| Ill et al., "Design and construction of a hybrid immunoglobulin domain with properties of both heavy and light chain variable regions," <i>Protein Engineering</i> , 10(8): 949-957 (1997)                                     |
| Jiang et al., "Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-I receptor," <i>Oncogene</i> , 18:6071-6077 (1999)   |
| Johnsson et al., "Comparison of methods for immobilization to carboxymethyl dextran sensor surfaces by analysis of the specific activity of monoclonal antibodies," <i>Journal of Molecular Recognition</i> , 8:125-131 (1995) |
| Johnsson et al., "Immobilization of proteins to a carboxymethylated gold surface for biospecific interaction analysis in surface plasmon resonance sensors," <i>Analytical Biochemistry</i> , 198:268-277 (1991)               |
| Jonsson et al., "Introducing a biosensor based technology for real-time biospecific interaction analysis," <i>Ann. Biologie Clinique</i> , 51:19-26 (1993)   |
| Jonsson et al., "Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology," <i>BioTechniques</i> , 11(5):620-627 (1991)   |
| Kaiser et al., "Expression of insulin-like growth factor receptors I and II in normal human lung and in lung cancer," <i>Journal of Cancer Research and Clinical Oncology</i> , 119(11):665-668 (1993)                         |
| Kalebic et al., " <i>In vivo</i> treatment with antibody against IGF-I receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34 <sup>cdc2</sup> ," <i>Cancer Research</i> , 54:5531-5534 (1994)             |

EXAMINER

DATE CONSIDERED

11/22/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.



U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

ATTY. DOCKET NO.  
ABX-PF2

APPLN. NO.  
10/038,591

APPLICANT  
Bruce D. C hen t al.

CONFIRMATION  
NO. 1445

FILING DATE  
January 4, 2002

GROUP  
1642

|  |   |
|--|---|
|  | Kim et al., "Insulin receptor substrate 2 and Shc play different roles in insulin-like growth factor I signaling," <i>Journal of Biological Chemistry</i> , 273:34543-34550 (1998)  |
|  | Lane, "A death in the life of p53," <i>Nature</i> , 362:786-787 (1993)  |
|  | LaPlanche et al., "Phosphorothiolate-modified oligodeoxyribonucleotides, III. NMR and UV spectroscopic studies of the R <sub>p</sub> -R <sub>p</sub> , S <sub>p</sub> -S <sub>p</sub> , and R <sub>p</sub> -S <sub>p</sub> duplexes, [d(GG <sub>5</sub> AATTCC)] <sub>2</sub> , derived from diastereomeric O-ethyl phosphorothioates," <i>Nucleic Acids Research</i> , 14(22):9081-9093 (1986) |
|  | Laron, "Clinical use of somatomedin-1," <i>Pediatric Drugs</i> , 1(3):155-159 (1999)  |
|  | LeRoith et al., "Molecular and cellular aspects of the insulin-like growth factor I receptor," <i>Endocrine Reviews</i> , 16(2):143-163 (1995)  |
|  | Li et al., "Mitogenicity and transforming activity of the insulin-like growth factor-I receptor with mutations in the tyrosine kinase domain," <i>Journal of Biological Chemistry</i> , 269:32558-32564 (1994)  |
|  | Macaulay, "Insulin-like growth factors and cancer," <i>British Journal of Cancer</i> , 65:311-320 (1992)  |
|  | Macaqueley et al., "Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells," <i>Cancer Research</i> , 50:2511-2517 (1990)   |
|  | Martin et al., "The affinity-selection of a minibody polypeptide inhibitor of human interleukin-6," <i>The EMBO Journal</i> , 13(22): 5303-5309 (1994)  |
|  | McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains," <i>Nature</i> , 348:552-554 (1990)   |
|  | McDonnell et al., "bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation," <i>Cell</i> , 57:79-88 (1989)   |
|  | Mendez et al., "Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice," <i>Nature Genetics</i> , 15:146-156 (1997)  |
|  | Moody et al., "Growth factor and peptide receptors in small cell lung cancer," <i>Life Sciences</i> , 52:1161-1173 (1993)   |
|  | Moyer et al., "Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase," <i>Cancer Research</i> , 57:4838-4848 (1997)  |

EXAMINER

DATE CONSIDERED

11/22/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not confirmed and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE  
STATEMENT BY APPLICANTATTY. DOCKET NO.  
ABX-PF2APPLN. NO.  
10/038,591APPLICANT  
Bruce D. C. hen et al.CONFIRMATION  
NO. 1445FILING DATE  
January 4, 2002GROUP  
1642

|                    |   |
|--------------------|---|
| <i>[Signature]</i> | Nakanishi et al., "Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro," <i>Journal of Clinical Investigation</i> , 82:354-359 (1988)  |
| <i>[Signature]</i> | Pearson, "Empirical statistical estimates for sequence similarity searches," <i>Journal of Molecular Biology</i> , 276:71-84 (1998)   |
| <i>[Signature]</i> | Pearson, "Rapid and sensitive sequence comparison with FASTP and FASTA," <i>Methods in Enzymology</i> , 183:63-98 (1990)  |
| <i>[Signature]</i> | Pearson, "Flexible sequence similarity searching with the FASTA3 program package," <i>Methods in Molecular Biology</i> , 132:185-219 (2000)   |
| <i>[Signature]</i> | Pearson, "Using the FASTA program to search protein and DNA sequence databases," <i>Methods in Molecular Biology</i> , 24:307-331 (1994)  |
| <i>[Signature]</i> | Pearson, "Effective protein sequence comparison," <i>Methods in Enzymology</i> , 266:227-258 (1996)   |
| <i>[Signature]</i> | Pietrzkowski et al., "Constitutive expression of insulin-like growth factor 1 and insulin-like growth factor 1 receptor abrogates all requirements for exogenous growth factors," <i>Cell Growth &amp; Differentiation</i> , 3:199-205 (1992)   |
| <i>[Signature]</i> | Pietrzkowski et al., "Roles of insulin-like growth factor 1 (IGF-1) and the IGF-1 receptor in epidermal growth factor-stimulated growth of 3T3 cells," <i>Molecular and Cellular Biology</i> , 12(9):3883-3889 (1992)   |
| <i>[Signature]</i> | Poljak, "Production and structure of diabodies," <i>Structure</i> , 2:1121-1123 (1994)  |
| <i>[Signature]</i> | Pollack et al., "Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice," <i>Journal of Pharmacology and Experimental Therapeutics</i> , 291(2):739-748 (1999) |
| <i>[Signature]</i> | Pollak et al., "Presence of somatomedin receptors on primary human breast and colon carcinomas," <i>Cancer Letters</i> , 38:223-230 (1987)  |
| <i>[Signature]</i> | Prager et al., "Dominant negative inhibition of tumorigensis <i>in vivo</i> by human insulin-like growth factor I receptor mutant," <i>PNAS</i> , 91:2181-2185 (1994)   |
| <i>[Signature]</i> | Remacle-Bonnet et al., "Expression of Type I, but not Type II insulin-like growth factor receptor on both undifferentiated and differentiated HT29 human colon carcinoma cell line," <i>Journal of Clinical Endocrinology and Metabolism</i> , 75(2):609-616 (1992)   |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in compliance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE  
STATEMENT BY APPLICANTATTY. DOCKET NO.  
ABX-PF2APPLN. NO.  
10/038,591APPLICANT  
Bruce D. C. Chen et al.CONFIRMATION  
NO. 1445FILING DATE  
January 4, 2002GROUP  
1642

|     |  |
|-----|--|
| 100 | Resnicoff et al., "The insulin-like growth factor I receptor protects tumor cells from Apoptosis <i>in vivo</i> ," <i>Cancer Research</i> , 55:2463-2469 (1995)  |
| 1   | Resnicoff et al., "Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors," <i>Cancer Research</i> , 55:3739-3741 (1995)   |
|     | Rizo et al., "Constrained peptides: models of bioactive peptides and protein substructures," <i>Annual Review of Biochemistry</i> , 61:387-418 (1992)  |
|     | Rodriguez-Tarduchy et al., "Insulin-like growth factor-I inhibits apoptosis in IL-3-dependent hemopoietic cells," <i>Journal of Immunology</i> , 149(2):535-540 (1992)   |
|     | Rosen et al., "Circulating IGF-I: new perspectives for a new century," <i>Trends in Endocrinology &amp; Metabolism</i> , 10(4):136-141 (1999)  |
|     | Sandberg-Nordqvist et al., "Characterization of insulin-like growth factor 1 in human primary brain tumors," <i>Cancer Research</i> , 53:2475-2478 (1993)  |
|     | Sell et al., "Insulin-like growth factor 1 (IGF-1) and the IGF-1 receptor prevent etoposide-induced apoptosis," <i>Cancer Research</i> , 55:303-306 (1995)   |
|     | Smith et al., "Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor," <i>Nature Medicine</i> , 5(12): 1390-1395 (1999)                       |
|     | Stec et al., "Automated solid-phase synthesis, separation, and stereochemistry of phosphorothioate analogues of oligodeoxyribonucleotides," <i>Journal of the American Chemical Society</i> , 106(20):6077-6079 (1984) |
|     | Stein et al., "Physicochemical properties of phosphorothioate oligodeoxynucleotides," <i>Nucleic Acids Research</i> , 16(8):3209-3221 (1988)   |
|     | Tappy et al., "Antibodies to insulin-like growth factor 1 receptors in diabetes and other disorders," <i>Diabetes</i> , 37:1708-1714 (1988)  |
| X   | Thompson et al., "Low prevalence of autoantibodies to the insulin-like growth factor I receptor in children with short stature," <i>Pediatric Research</i> , 32(4):455-459 (1988)                                      |
|     | Thornton et al., "Prediction of progress at last," <i>Nature</i> , 354(14):105-106 (1991)  |
| WJ  | Traunecker et al., "Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells," <i>The EMBO Journal</i> , 10(12):3655-3659 (1991)  |

EXAMINER

DATE CONSIDERED 1/22/01

EXAMINER: Initial if citation considered, whether or not citation is in compliance with MPEP 609; Draw line through citation if not considered. Include copy of this form with next communication to applicant.



|  |  |                                    |                          |
|--|--|------------------------------------|--------------------------|
| FORM PTO-1449                                    | U.S. DEPARTMENT OF COMMERCE<br>PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO.<br>ABX-PF2        | APPLN. NO.<br>10/038,591 |
| INFORMATION DISCLOSURE<br>STATEMENT BY APPLICANT |  | APPLICANT<br>Bruce D. C hen et al. | CONFIRMATION<br>NO. 1445 |
|  |  | FILING DATE<br>January 4, 2002     | GROUP<br>1642            |

|  |   |
|--|---|
|  | Traunecker et al., "Janusin: new molecular design for bispecific reagents," <i>International Journal of Cancer</i> , 7:51-52 (1992)   |
|  | Trojan et al., "Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor 1 RNA," <i>Science</i> , 259:94-97 (1993)  |
|  | Uhlmann et al., "Antisense oligonucleotides: a new therapeutic principle," <i>Chemical Reviews</i> , 90(4):543-584 (1990)   |
|  | Ullrich et al., "Signal transduction by receptors with tyrosine kinase activity," <i>Cell</i> , 61:203-212 (1990)   |
|  | Ullrich et al., "Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity," <i>The EMBO Journal</i> , 5(10):2503-2512 (1986) |
|  | Veber et al., "The design of metabolically-stable peptide analogs," <i>TINS</i> , 8(9):392-396 (1985)   |
|  | Ward et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from <i>Escherichia coli</i> ," <i>Nature</i> , 341:544-546 (1989)  |
|  | Weightman et al., "Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy," <i>Autoimmunity</i> , 16:251-257 (1993)   |
|  | Williams, "Programmed cell death: apoptosis and oncogenesis," <i>Cell</i> , 65:1097-1098 (1991)   |
|  | Winter et al., "Humanized antibodies," <i>Immunology Today</i> , 14(6):243-246 (1993)   |
|  | Wraight et al., "Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth factor I receptor antisense oligonucleotides," <i>Nature Biotechnology</i> , 18:521-526 (2000)                                      |
|  | Wright et al., "Genetically engineered antibodies: progress and prospects," <i>Critical Reviews in Immunology</i> , 12:(3,4)125-168 (1992)  |
|  | Yee et al., "Analysis of insulin-like growth factor 1 gene expression in malignancy: evidence for a paracrine role in human breast cancer," <i>Molecular Endocrinology</i> , 3(3):509-517 (1989)                                  |
|  | Yee et al., "Insulin-like growth factor II mRNA expression in human breast cancer," <i>Cancer Research</i> , 48:6691-6696 (1988)  |
|  | Zon et al., "Phosphorothioate oligonucleotides," <i>Oligonucleotides and Analogues: A Practical Approach</i> , 87-108 (F. Eckstein, Ed., Oxford University Press, Oxford England (1991))  |

EXAMINER

DATE CONSIDERED

11/22/04

EXAMINER: Initial if citation considered, whether or not citation is in compliance with MPEP 609; Draw line through citation if not compliance and not considered. Include copy of this form with next communication to applicant.

|   |  |                                   |                          |
|---|--|-----------------------------------|--------------------------|
| FORM PTO-1449   | U.S. DEPARTMENT OF COMMERCE<br>PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO.<br>ABX-PF2       | APPLN. NO.<br>10/038,591 |
|  | INFORMATION DISCLOSURE<br>STATEMENT BY APPLICANT           | APPLICANT<br>Bruc D. Cohen et al. | CONFIRMATION<br>NO. 1445 |
|   |  | FILING DATE<br>January 4, 2002    | GROUP<br>1642            |

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

**ATTY. DOCKET NO.  
ABX-PF2**

**APPLN. NO.**  
**10/038,591**

**APPLICANT**  
Bruce D. Cohen et al.

**CONFIRMATION  
NO. 1445**

**FILING DATE**  
January 4, 2002

**GROUP  
1642**

WPA

Zon et al., "Phosphorothioate oligonucleotides: chemistry, purification, analysis, scale-up and future directions," *Anti-Cancer Drug Design*, 6:539-568 (1991)

**EXAMINER**

**DATE CONSIDERED**

11/22/04

**EXAMINER:** Initial if citation considered, whether or not citation is in conflict with MPEP 609; Draw line through citation if not conflict and not considered. Include copy of this form with next communication to applicant.